Actively Recruiting
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Led by Divaya Bhutani · Updated on 2025-06-08
39
Participants Needed
2
Research Sites
178 weeks
Total Duration
On this page
Sponsors
D
Divaya Bhutani
Lead Sponsor
G
Genzyme, a Sanofi Company
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
CONDITIONS
Official Title
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple myeloma, relapsed/refractory Hodgkin's disease, or specific types of relapsed/refractory non-Hodgkin's lymphoma including diffuse large B cell lymphoma, indolent B cell lymphomas, mantle cell lymphoma, or peripheral T cell lymphoma
- Undergoing first autologous stem cell transplant
- Any prior therapy allowed except CD38 antibody treatment within the last 12 months
- Age 18 years or older
- Life expectancy greater than 6 months
You will not qualify if you...
- Received CD38 antibody treatment within the last 12 months
- Receiving other investigational agents currently or within the last 8 weeks
- History of severe allergic reactions to compounds similar to Isatuximab
- Uncontrolled illness including active infection, heart failure, unstable angina, arrhythmia, or psychiatric/social conditions limiting study compliance
- Pregnant or lactating women
- HIV positive status
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
2
Columbia University
New York, New York, United States, 10032
Actively Recruiting
Research Team
R
Research Nurse Navigator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here